Ventyx biosciences reports third quarter 2023 financial results and highlights recent corporate progress

Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 cash, cash equivalents and marketable securities of $300.8 million as of september 30, 2023 san diego, nov. 09, 2023 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx) (“ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended september 30, 2023, and highlighted recent pipeline and business progress. “we are committed to progressing our wholly-owned portfolio of novel small molecule drug candidates,” said raju mohan, chief executive officer.
VTYX Ratings Summary
VTYX Quant Ranking